ArticleFrontiers in medicine2026
Intrapleural hemocoagulase Bothrops atrox and early outcomes after VATS for stage IA non-small cell lung cancer.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemocoagulase Bothrops atrox (HBA) is used to reduce surgical bleeding, but its impact on postoperative coagulation after video-assisted thoracoscopic surgery (VATS) remains unclear. We evaluated the effects of intrapleural HBA on coagulation profiles and early recovery in stage IA non-small cell lung cancer (NSCLC). Methods: We retrospectively analyzed 442 stage IA NSCLC patients undergoing VATS, allocated to HBA ( Results: After IPTW adjustment, intrapleural HBA was associated with a longer prothrombin time (PT; 12.83 ± 0.99 vs. 12.31 ± 1.50 s; Conclusion: Intrapleural HBA injection in stage IA NSCLC undergoing VATS is associated with modest alterations in coagulation (prolonged PT and reduced FIB) and improved early outcomes, including fewer complications and shorter hospitalization. Prospective studies are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.